Genotoxicity of Retroviral Integration In Hematopoietic Cells

Molecular Therapy

Volumn 13, Issue 6, 2006, Pages 1031-1049

  Nienhuis, Arthur W ^a   Dunbar, Cynthia E ^b   Sorrentino, Brian P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

gene therapy; insertional mutagenesis; neoplasia; proto oncogene activation; retroviral vectors

Indexed keywords

IMMUNOMODULATING AGENT; LENTIVIRUS VECTOR; PROTEIN LMO2; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

BONE MARROW CELL; CELL CULTURE; CELL POPULATION; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DISEASE MODEL; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GENETIC TRANSDUCTION; GENOTOXICITY; HEMATOPOIETIC CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMOGENESIS; LONG TERMINAL REPEAT; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PATHOGENESIS; PROTO ONCOGENE; REVIEW; RISK ASSESSMENT; SAFETY; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; X CHROMOSOME LINKED DISORDER;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENHANCER ELEMENTS (GENETICS); GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC SYSTEM; HUMANS; LEUKEMIA; LYMPHOPROLIFERATIVE DISORDERS; METALLOPROTEINS; MICE; MUTAGENICITY TESTS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENES; RETROVIRIDAE; SEVERE COMBINED IMMUNODEFICIENCY; VIRUS INTEGRATION;

ANIMALIA; LENTIVIRUS;

EID: 33646887376     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2006.03.001     Document Type: Review

References (139)

1. Mann R., Mulligan R.C., and Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33 (1983) 153-159
2. Williams D.A., Lemischka I.R., Nathan D.G., and Mulligan R.C. Introduction of a new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 310 (1984) 476-480
3. Cavazzana-Calvo M., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
4. Hacein-Bey-Abina S., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346 (2002) 1185-1193
5. Gaspar H.B., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gamma-retroviral vector. Lancet 364 (2004) 2181-2187
6. Thrasher A.J., et al. Failure of SCID-X1 gene therapy in older patients. Blood 105 (2005) 4255-4257
7. Aiuti A., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296 (2002) 2410-2413
8. Kohn D.B., et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat. Med. 4 (1998) 775-780
9. Malech H.L., Choi U., and Brenner S. Progress toward effective gene therapy for chronic granulomatous disease. Jpn. J. Infect. Dis. 57 (2004) S27-S28
10. Siler U., et al. Chronic granulomatous disease gene therapy functionally corrects the phenotype of polymorphonuclear leukocytes (PMN). Mol. Ther. 11 (2005) S129
11. Ott M.G., et al. Long-term follow-up of patients successfully treated by gene therapy for X-linked chronic granulomatous disease. Blood 106 Suppl. 1 (2005) 60a
12. Gaspar H., et al. Somatic gene therapy for ADA-SCID following cessation of PEG-ADA and use of a mild conditioning regime. Mol. Ther. 11 (2005) S13
13. Hacein-Bey-Abina S., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348 (2003) 255-256
14. Hacein-Bey-Abina S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
15. Check E. Gene therapy put on hold as third child develops cancer. Nature 433 (2005) 561
16. Frederickson R.M. Report from the 2nd stem cell clonality and genotoxicity retreat. Mol. Ther. 12 (2005) 379-383
17. Schwarzwaelder K., et al. Myeloid expansion after insertional activation of MDS/EVI1, PRDM16 and SE+BP1 in a successful chronic granulomatous gene therapy trial. Blood 106 Suppl. 1 (2005) 61a
18. Cavazzana-Calvo M., Thrasher A., and Mavilio F. The future of gene therapy: balancing the risks and the benefits of clinical trials. Nature 427 (2004) 779-781
19. Hoag H. Gene therapy rising?. Nature 435 (2005) 530-531
20. Hanawa H., et al. Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a Simian Immunodeficiency Virus-based lentiviral vector system. Blood 103 (2004) 4062-4069
21. Relander T., et al. Gene transfer to repopulating human CD34+ cells using amphotrophic-, GALV-, or .RD114-pseudotyped HIV-1-based vectors from stable producer cells. Mol. Ther. 11 (2004) 452-459
22. Lucas M., et al. Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes. Blood 106 (2005) 51-58
23. Pinkel D. Treatment of childhood acute lymphocytic leukemia. J. Pediatr. 77 (1970) 1089-1091
24. Pui C.H., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital. Blood 104 (2004) 2690-2696
25. Relling M.V., et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101 (2003) 3862-3867
26. Relling M.V., et al. High incidence of secondary brain tumors after radiotherapy and antimetabolites. Lancet 354 (1999) 34-39
27. Blaese R.M., et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270 (1995) 475-480
28. Muul L.M., et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101 (2003) 2563-2569
29. Malech H.L., et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 12133-12138
30. Kohn D.B., et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral mediated gene transfer to hematopoietic stem cells. Mol. Ther. 8 (2003) 180-187
31. Orkin, S.H., Motulsky, A.G. (1995). Report and recommendations of the panel to assess the NIH investment in research on gene therapy. http://www.nih.gov/news/panelrep.html.
32. Fischer A., et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol. Rev. 203 (2005) 98-109
33. Raper S.E., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80 (2003) 148-158
34. Gelsinger P. Jesse's intent. In: Ambur R., and Bankert E. (Eds). Institutional Review Board: Management and Function (2002), Jones and Barlett Publishers, Sandbury, MA xi-xix
35. Couzin J., and Kaiser J. As Gelsinger case ends, gene therapy suffers another blow. Science 307 (2005) 1028
36. Kohn D.B., Sadelain M., and Glorioso J.C. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev., Cancer 3 (2003) 477-488
37. Baum C., et al. Review in translational hematology. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101 (2003) 2099-2113
38. Fehse B., Kustikova O.S., Bubenheim M., and Baum C. Pois(s)on-It's a question of dose. Gene Ther. 11 (2004) 879-881
39. Baum C., et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol. Ther. 9 (2004) 5-13
40. von Kalle C., Behse B., Layh-Schmitt G., Schmidt M., Kelly P., and Baum C. Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable. Semin. Hematol. 41 4 (2004) 303-318
41. Kang E., and Tisdale J. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications. Curr. Hematol. Rep. 3 (2004) 274-281
42. Sadelain M. Insertional oncogenesis in gene therapy: how much of a risk?. Gene Ther. 11 (2004) 569-573
43. McCormack M.P., and Rabbitts T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350 (2004) 913-922
44. Rabbitts T.H., Bucher K., Chung G., Grutz G., Warren A., and Yamada Y. The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development. Cancer Res. 59 7 Suppl. (1999) 1794s-1798s
45. Royer-Pokora B., Loos U., and Ludwig W.D. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 6 (1991) 1887-1893
46. Larson R.C., Osada H., Larson T.A., Lavenir I., and Rabbitts T.H. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene 11 (1995) 853-862
47. Neale G.A., Rehg J.E., and Goorha R.M. Ectopic expression of rhombotin-2 causes selective expansion of CD4-CD8- lymphocytes in the thymus and T-cell tumors in transgenic mice. Blood 86 (1995) 3060-3071
48. Schroder A.R., Shinn P., Chen H., Berry C., Ecker J.R., and Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110 (2002) 521-529
49. Wu X., Li Y., Crise B., and Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300 (2003) 1749-1751
50. Hematti P., et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2 (2004) e423
51. Laufs S., Nagy K.Z., Giordano F.A., Hotz-Wagenblatt A., Zeller W.J., and Fruehauf S. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol. Ther. 10 (2004) 874-881
52. Imren S., et al. High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J. Clin. Invest. 114 (2004) 953-962
53. Kustikova O., et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308 (2005) 1171-1174
54. DesGroseillers L., and Jolicoeur P. Mapping the viral sequences conferring leukemogenicity and disease specificity in Moloney and amphotrophic murine leukemia viruses. J. Virol. 52 (1984) 448-456
55. Li Y., Golemis E., Hartley J.W., and Hopkins N. Disease specificity of nondefective Friend and Moloney murine leukemia viruses is controlled by a small number of nucleotides. J. Virol. 61 (1987) 693-700
56. Hacein-Bey H., et al. Gamma-c gene transfer into SCID X1 patient's B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood 87 (1996) 3108-3116
57. Riviere I., Brose K., and Mulligan R.C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 6733-6737
58. Gardie B., Cayuela J.M., Martini S., and Sigaux F. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 9 (1998) 1016-1020
59. Suzuki T., et al. New genes involved in cancer identified by retroviral tagging. Nat. Genet. 32 (2002) 166-174
60. Dave U.P., Jenkins N.A., and Copeland N.G. Gene therapy insertional mutagenesis insights. Science 303 (2004) 333
61. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004) 137-148
62. Meyerrose T.E., Herrbrich P., Hess D.A., and Nolta J.A. Immune-deficient mouse models for analysis of human stem cells. Biotechniques 35 (2003) 1262-1272
63. Buckley R.H., et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 340 (1999) 508-516
64. Antoine C., et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 361 (2003) 553-560
65. Lo M., et al. Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach. Blood 94 (1999) 3027-3036
66. Soudais C., et al. Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer. Blood 95 (2000) 3071-3077
67. Otsu M., Anderson S.M., Bodine D.M., Puck J.M., O'Shea J.J., and Candotti F. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol. Ther. 1 (2000) 145-153
68. Schmidt M., et al. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood 105 (2005) 2699-2706
69. Adler R.L., et al. Analysis of clonal contributions to T lymphoid and myeloid lineages during early hematopoiesis following autologous transplantation in the rhesus macaque. Blood 104 Suppl. 1 (2004) 730a
70. Hacein-Bey S., et al. Optimization of retroviral gene transfer protocol to maintain the lymphoid potential of progenitor cells. Hum. Gene Ther. 12 (2001) 291-301
71. Ficara F., et al. IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential. Mol. Ther. 10 (2004) 1096-1108
72. Kempler G., Freitag B., Berwin B., Nanassy O., and Barklis E. Characterization of the Moloney murine leukemia virus stem cell-specific repressor binding site. J. Virol. 193 (1993) 690-699
73. Modin C., Lund A.H., Schmitz A., Duch M., and Pedersen F.S. Alleviation of murine leukemia virus repression in embryonic carcinoma cells by genetically engineered primer binding sites and artificial tRNA primers. J. Virol. 278 (2000) 368-379
74. Shou Y., Stepanova L., and Sorrentino B.P. Mouse models for the analysis of genetic risk factors for hematopoietic transformation in XSCID gene therapy. Mol. Ther. 11 Suppl. 1 (2004) S176
75. Kamijo T., Bodney S., van de Kamp E., Randle D.H., and Sherr C.J. Tumor spectrum in ARF-deficient mice. Cancer Res. 59 (1999) 2217-2222
76. Kiem H.P., et al. Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia. Mol. Ther. 9 (2004) 389-395
77. Li Z., et al. Murine leukemia induced by retroviral gene marking. Science 296 (2002) 497
78. Bunting K.D., Galipeau J., Topham D., Benaim E., and Sorrentino B.P. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood 92 (1998) 2269-2279
79. Modlich U., et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR 1) are driven by combinatorial insertional mutagenesis. Blood 105 (2005) 4235-4246
80. Seggewiss R., et al. Acute myeloid leukemia associated with retroviral gene transfer to hematopoietic progenitor cells of a rhesus macaque. Blood (2006, Jan 26) (Electronic publication ahead of print)
81. Moreb J.S., and Schweder M. Human A1, a Bc1-2-related gene, is induced in leukemic cells by cytokines as well as differentiating factors. Leukemia 11 (1997) 998-1004
82. Kelly P.F., et al. Prolonged multilineage clonal hematopoiesis in a rhesus recipient of CD34+ cells marked with a RD114 pseudotyped oncoretroviral vector. Blood Cells Mol. Dis. 30 (2003) 132-143
83. Persons D.A., et al. Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood 103 (2004) 796-803
84. Du Y., Jenkins N.A., and Copeland N.G. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 106 (2005) 3932-3939
85. Emery D.W., Li C., and Stamatoyannopoulos G. Use of the cHS4 chromatin insulator to reduce oncoretrovirus vector-mediated genotoxicity. Mol. Ther. 11 Suppl. 1 (2005) s150
86. Calmels B., et al. Recurrent retroviral vector integration at the MDS1-EVI1 locus in non-human primate hematopoietic cells. Blood 106 (2005) 2530-2533
87. Buonamici S., et al. EVI1 induces myelodysplastic syndrome in mice. J. Clin. Invest. 114 (2004) 713-719
88. Barjesteh van Waalwjik van Doom-Khosrovani S., et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101 (2003) 837-845
89. Mitani K. Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene 23 (2004) 4263-4269
90. Bushman F., et al. Genome-wide analysis of retroviral DNA integration. Nat. Rev., Microbiol. 3 (2005) 848-858
91. Coffin J.M., Hughes S.H., and Varmus H.E. Retroviruses (1997), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
92. Bor Y.C., Miller M.D., Bushman F.D., and Orgel L.E. Target-sequence preferences of HIV-1 integration complexes in vitro. Virology 222 (1996) 283-288
93. Brown P.O., Bowerman B., Varmus H.E., and Bishop J.M. Correct integration of retroviral DNA in vitro. Cell 3 (1987) 347-356
94. Wu X., Li Y., Crise B., Burgess S.M., and Munroe D.J. Weak palindromic consensus sequences are a common feature found at the integration target sites of many retroviruses. J. Virol. 79 (2005) 5211-5214
95. Pryciak P.M., Sil A., and Varmus H.E. Retroviral integration into minichromosomes in vitro. EMBO J. 11 (1992) 291-303
96. Pruss D., Bushman F.D., and Wolffe A.P. Human immunodeficiency virus integrase directs integration to sites of severe DNA distortion within the nucleosome core. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 5913-5917
97. Scherdin U., Rhodes K., and Breindl M. Transcriptionally active genome regions are preferred targets for retrovirus integration. J. Virol. 64 (1990) 907-912
98. Vijava S., Steffen D.L., and Robinson H.L. Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin. J. Virol. 60 (1986) 683-692
99. Lander E., et al. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
100. Venter J.C. The sequence of the human genome. Science 291 (2001) 1304-1351
101. Schmidt M., et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood 100 (2002) 2737-2743
102. Crise B., et al. Simian immunodeficiency virus integration preference is similar to that of human immunodeficiency virus type 1. J. Virol. 79 (2005) 12199-12204
103. Mitchell R.S., et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2 (2004) E234
104. Trobridge G., Vassilopoulos G., Josephson N., and Russell D.W. Gene transfer with foamy virus vectors. Methods Enzymol. 346 (2002) 628-648
105. Trobridge G., et al. Foamy virus vector integration sites in normal human cells. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 1498-1503
106. De Palma M., et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105 (2005) 2307-2315
107. Ryu B., Persons D., and Nienhuis A.W. The effect of globin locus control region (LCR) elements of the MSCV-LTR on promoter trapping by integrated lentiviral vector genomes. Mol. Ther. 11 Suppl. 1 (2005) S4
108. Bushman F.D. Targeting survival: integration site selection by retroviruses and LTR-retrotransposons. Cell 115 (2003) 135-138
109. Sandmeyer S. Integration by design. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 5586-5588
110. Ciceri F., and Bordignon C. Suicide-gene-transducer donor T-cells for controlled graft-versus-host disease and graft-versus-tumor. Int. J. Hematol. 76 (2002) 305-309
111. Bonini C., et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat. Med. 9 (2003) 367-369
112. Recchia A., et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 1457-1462
113. Hargrove P., et al. Assessment of changes in gene expression caused by insertions of a globin lentiviral vector containing globin regulatory elements or a lentiviral vector containing retroviral LTR elements. Blood 104 (2004) 145
114. Zamore P.D., and Haley B. Ribo-gnome: the big world of small RNAs. Science 309 (2005) 1519-1524
115. Claverie J.M. Fewer genes, more noncoding RNA. Science 309 (2005) 1529-1530
116. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
117. Chen C.Z., Li L., Lodish H.F., and Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 303 (2004) 83-86
118. Chen C.Z., and Lodish H.F. MicroRNAs as regulators of mammalian hematopoiesis. Semin. Immunol. 17 (2005) 155-156
119. Calin G.A., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15524-15529
120. Calin G.A., et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11755-11760
121. Calin G.A., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2993-3004
122. -/- stem/progenitor cells predisposes cells to undergo apoptosis, and surviving stem/progenitor cells display cytogenetic abnormalities and an increased risk of malignancy. Blood 105 (2005) 3465-3471
123. Woods N.B., et al. Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood 101 (2003) 1284-1289
124. Zanjani E.D., Almeida-Porada G., Livingston A.G., Zeng H., and Ogawa M. Reversible expression of CD34 by adult human bone marrow long-term engrafting hematopoietic stem cells. Exp. Hematol. 31 (2003) 406-412
125. Montini E. Testing the oncogenic potential of retroviral and lentiviral vector integration. Mol. Ther. 11 Suppl. 1 (2005) s150-s151
126. Yu S.F., et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 3194-3198
127. Zufferey R., et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72 (1998) 9873-9880
128. Zaiss A.K., Son S., and Chang L.J. RNA 3′ read through of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J. Virol. 76 (2002) 7209-7219
129. West A.G., Gaszner M., and Felsenfeld G. Insulators: many functions, many mechanisms. Genes Dev. 16 (2002) 271-288
130. Recillas-Targa F., et al. Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 6883-6888
131. Felsenfeld G., et al. Chromatin boundaries and chromatin domains. Cold Spring Harb. Symp. Quant. Biol. 69 (2004) 245-250
132. Harrison D.A., Geyer P.K., Spana C., and Corces V.G. The gypsy retrotransposons of Drosophila melanogaster: mechanisms of mutagenesis and interaction with the suppressor of Hairy-wing locus. Dev. Genet. 10 (1989) 239-248
133. Emery D.W., Yannaki E., Tubb J., Nishino T., Li O., and Stamatoyannopoulos G. Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 100 (2002) 2012-2019
134. Ramezani A., Hawley T.S., and Hawley R.G. Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 101 (2003) 4717-4724
135. Puthenveetil G., et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 104 (2004) 3445-3453
136. Recillas-Targa F., Valadez-Graham V., and Farrell C.M. Prospects and implications of using chromatin insulators in gene therapy and transgenesis. BioEssays 26 (2004) 796-807
137. Spencer D.M. Developments in suicide genes for preclinical and clinical applications. Curr. Opin. Mol. Ther. 2 (2000) 433-440
138. Uckert W., et al. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum. Gene Ther. 9 (1998) 855-865
139. Frank O., et al. Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood 104 (2004) 3543-3549